阶段新高，沪指再突破！银行全线走牛，农行续刷新高，港股创新药大反攻，高人气520880领涨居前

Market Overview - A-shares opened higher and closed with all three major indices rising, with the Shanghai Composite Index increasing nearly 1% to close at 3617.6 points, marking a new high for the closing price [1] - The total trading volume of the two markets reached 1.6 trillion yuan, with over 3900 stocks rising [1] ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) rose by 2.73%, leading the market in ETF gains, with a trading volume exceeding 800 million yuan [5][10] - The Bank ETF (512800) gained 1.52%, marking its third consecutive day of gains after a period of correction [2][3] - The Real Estate ETF (159707) and Value ETF (510030) also saw increases of over 1% [2] Sector Highlights - The banking sector showed strong performance, with Agricultural Bank rising over 2% and setting a new historical high [2][3] - The financial technology sector rebounded in the afternoon, with notable performances from the Financial Technology ETF (159851) and the Broker ETF (512000) [3][14] - The innovative drug sector in Hong Kong saw significant interest, with the Innovative Drug ETF (520880) attracting substantial capital, reflecting a 123% increase in fund size since its launch [3][10] Individual Stock Movements - Among the top-performing stocks, Lepu Biopharma-B, Ascentage Pharma-B, and CanSino Biologics-B saw double-digit percentage increases [7][9] - CanSino Biologics reported a significant milestone with its dual-action drug entering Phase III clinical trials, contributing to its stock price increase of over 7% [9] - The report from Morgan Stanley highlighted that the biopharmaceutical sector is benefiting from business development (BD) activities, with companies like Innovent Biologics expected to gain significantly [9] Investment Trends - The innovative drug sector is experiencing a boom, with 43 new innovative drugs approved in the first half of the year, a 59% increase year-on-year [9][10] - The introduction of supportive policies, such as a five-year price stability period for newly launched drugs, is expected to enhance the profitability of innovative drug companies [10][20] - The Value ETF (510030) focuses on high-dividend and low-valuation blue-chip stocks, which are expected to benefit from the current market conditions [20][21]